Mafusol, vials, 400ml

Composition

Pharmacological action

The drug effectively corrects water-salt metabolism, helps to reduce tissue hypoxia.

Sodium fumarate is found in all cells of the body with an aerobic type of respiration, helps to eliminate acidemia by chemical neutralization of acidic metabolic products like lactate and sodium acetate (components widely used in the manufacture of salt solutions).

This drug reduces blood viscosity and improves its rheological properties and hemodynamic parameters, has a diuretic and detoxification effect.

Pharmacokinetics

Data on the pharmacokinetics of the drug Mafusol are not provided.

Indications

Hypovolemic and hypoxic states of various etiologies:

• blood loss;
• shock (hemorrhagic, burn, traumatic, surgical);
• intoxication (including peritonitis, sepsis, intestinal obstruction);
• trauma.

As a component of the perfusion mixture for filling the cardiopulmonary bypass device.

Contraindications

Conditions in which a large amount of fluid should not be introduced into the body, including:

• increased intracranial pressure with a closed skull injury;
• chronic heart failure in the decompensation stage.

Side effects

When used as indicated in the recommended doses, no side effects were observed.

Interaction

Drug interaction of the drug has not been studied.

How to take, course of use and dosage

The drug is administered intravenously and intravenously. The dose and rate of use are set individually, depending on the indications and the patient’s condition.

In case of mild to moderate shock, the drug is administered intravenously and intravenously in a jet. After normalization of hemodynamic parameters-iv drip in a daily dose of 2-2.5 l. In severe shock, the introduction of Mafusol (at least 1 l/day) is combined with the introduction of blood and colloidal blood substitutes of hemodynamic action.

In severe intoxications, the drug is administered at a dose of up to 2-3 liters/day in combination with other detoxification drugs.

When filling the cardiopulmonary bypass device, Mafusol makes up to 50-70% of the total volume of perfusion solution introduced into the device.

Overdose

Data on overdose of the drug Mafusol are currently unavailable.

Special instructions

Mafusol can be used in combination with blood and colloidal blood substitutes of hemodynamic action, as well as in combination with other detoxifying agents.

Form of production

Solution for infusions

Storage conditions

At a temperature of 0-25 °C

Shelf life

2 years

Active ingredient

Potassium Chloride, Magnesium Chloride, Sodium Chloride, Sodium Fumarate

Conditions of release from pharmacies

By prescription

Dosage form

infusion solution